



Biofunctional study on chemoresistance in esophageal squamous carcinoma cells induced by missense mutation of *NOTCH1 p.E450K*

Keting Li^{1#}, Wentao Hao^{2#}, Jiwei Wu¹, Xianben Liu¹, Wenqun Xing¹, Yan Zheng¹

¹Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China;

²Department of Thoracic Surgery, Shanghai Public Health Clinical Center, Shanghai, China

Contributions: (I) Conception and design: J Wu, W Hao, K Li, Y Zheng; (II) Administrative support: X Liu, W Xing; (III) Provision of study materials or patients: W Xing, X Liu; (IV) Collection and assembly of data: W Hao, K Li; (V) Data analysis and interpretation: W Hao, K Li, Y Zheng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work as co-first authors.

Correspondence to: Yan Zheng, MD, PhD. Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Road, Zhengzhou 450008, China. Email: sunnyzheng1@126.com.

Background: Neoadjuvant chemotherapy (nCT) combined with surgery is one of the main strategies for the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC). However, nearly 40% of patients did not benefit from nCT, and the detection rate of *NOTCH1* missense mutation was significantly increased in patients who did not respond to chemotherapy, suggesting that the missense mutation may be related to tumor chemoresistance. We aim to explore the effect of a *NOTCH1* missense mutation on cell phenotype, to interpret the biofunctional changes in cell lines with a *NOTCH1* missense mutation and to analyze the effect of a *NOTCH1* missense mutation on drug resistance in ESCC cell lines.

Methods: Sanger sequencing was used to evaluate the exon mutations in the *NOTCH1* ligand binding region of candidate ESCC cell lines. After screening, KYSE450 and KYSE140 cells were selected as the research objects, and point mutation cell lines [KYSE140-mutant-type (MT) and KYSE450-MT] were constructed by CRISPR/Cas9 technology. Then, functional experiments were performed with the four cell lines [KYSE450-MT/wild-type (WT) and KYSE140-MT/WT]. The drug resistance of ESCC cell lines was assessed with a drug sensitivity test, and the proliferation, invasion and migration of ESCC lines were evaluated by proliferation test, scratch test and Transwell test. The cell cycle status of ESCC cells was assessed using flow cytometry.

Results: Drug sensitivity tests showed that the *NOTCH1 p.E450K* point mutation caused chemotherapy resistance in KYSE140 and KYSE450 ESCC cell lines. Cell proliferation, Wound scratch and Transwell assays showed that the *NOTCH1 p.E450K* point mutation enhanced the proliferation, invasion and migration abilities of KYSE140 and KYSE450 cells. Flow cytometry analysis showed that the *NOTCH1 p.E450K* point mutation caused an increase in KYSE140 and KYSE450 cells in S phase.

Conclusions: The *NOTCH1 p.E450K* point mutation causes chemotherapy resistance in KYSE140 and KYSE450 ESCC cells. Cell functional experiments showed that the *NOTCH1 p.E450K* point mutation enhanced the proliferation, migration and invasion abilities of KYSE140 and KYSE450 cells and increased the number of cells in S phase.

Keywords: *NOTCH1*; esophageal squamous cell carcinoma (ESCC); chemotherapy resistance

Submitted Dec 10, 2023. Accepted for publication Feb 16, 2024. Published online Feb 21, 2024.

doi: 10.21037/jtd-23-1880

View this article at: <https://dx.doi.org/10.21037/jtd-23-1880>

Introduction

Esophageal cancer is a common malignant tumor of the gastrointestinal tract. In 2020, the incidence and mortality of esophageal cancer worldwide ranked eighth and sixth, respectively, among all malignant tumors (1). The main pathological types of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). More than half of ESCC cases worldwide are in China (2).

Neoadjuvant chemotherapy (nCT) combined with surgery is one of the main strategies for the treatment of resectable locally advanced ESCC. However, nearly 40% of patients do not benefit from nCT, and approximately 5% even experience progression (3), suggesting that these patients may have drug resistance mutations. In response to the chemotherapy resistance of some tumors, many scholars have conducted screening studies on drug-resistant mutations in the hope of improving the efficacy of chemotherapy (4). Some studies have shown that the abnormal activation of the *NOTCH* signaling pathway is closely associated with the occurrence,

development, invasion, and metastasis of many tumors (5,6). It has been confirmed in esophageal cancer and other tumors that the activation of the *NOTCH1/HES1* pathway can lead to tumor chemotherapy resistance (7,8). However, most of these studies addressed the regulation of *NOTCH1* transcription or expression and the subsequent abnormal activation of the *NOTCH1/HES1* pathway leading to drug resistance. To date, no studies have shown that *NOTCH1* missense mutations affect the ligand binding status of receptors in this pathway to cause drug resistance. A previous study (9) on resistance to nCT in esophageal cancer showed that the detection rate of *NOTCH1* missense mutations was significantly increased in patients with ineffective nCT. Further study showed that *NOTCH1 p.E450K* was the only mutation that was being repeatedly detected. Our previous study showed that the *NOTCH1 p.E450K* (p.Glu450Lys) missense mutation may lead to tighter binding of the mutant protein to the *DLL4* receptor, thereby continuously activating downstream signaling pathways (10). Missense mutations may alter drug effects by affecting cell signaling pathways. Based on this, we used a series of experiments to investigate the effect of a *NOTCH1* missense mutation on cell phenotype, to elucidate the biological and functional changes in cell lines with a *NOTCH1* missense mutation and to systematically analyze the effect of the *NOTCH1 p.E450K* missense mutation on the drug resistance of ESCC cells. We present this article in accordance with the MDAR reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1880/rc>).

Highlight box

Key findings

- The *NOTCH1 p.E450K* point mutation causes chemotherapy resistance in KYSE140 and KYSE450 esophageal squamous cell carcinoma (ESCC) cells.

What is known and what is new?

- The detection rate of *NOTCH1* missense mutations was significantly increased in patients with ineffective neoadjuvant chemotherapy (nCT). Further study showed that *NOTCH1 p.E450K* was the only mutation that was being repeatedly detected.
- We elucidate the biological and functional changes in cell lines with a *NOTCH1* missense mutation and systematically analyze the effect of the *NOTCH1 p.E450K* missense mutation on the drug resistance of ESCC cells.

What is the implication, and what should change now?

- ESCC is a malignant tumor with high incidence and strong invasiveness. nCT combined with surgery is one of the main strategies for the treatment of resectable locally advanced ESCC. Although nCT has achieved good effects, resistance of tumor cells to chemotherapy is still a problem. If the mechanism underlying the involvement of the *NOTCH* signaling pathway in cell drug resistance is elucidated, it may provide new therapeutic targets and targeted pathways for molecular targeted therapy for the reversal of drug resistance in esophageal cancer. This missense mutation may be a potential predictor of clinical chemotherapy efficacy and an important target for the reversal of drug resistance, which is worthy of further study.

Methods

Cell lines and Sanger sequencing

ESCC cell lines KYSE140, KYSE150, KYSE410, KYSE450, and KYSE510 (from the Hormel Research Institute of Henan Cancer Hospital, a donation from Professor Kangdong Liu) were chosen as candidate cells. The DNA of relevant cells was extracted and subjected to polymerase chain reaction (PCR) amplification and electrophoresis, and after purification, sequencing screening was performed. According to the sequencing results, KYSE140 and KYSE450 cells were selected as the research objects of this experiment. Sanger sequencing was performed at BGI Genomics (Shenzhen, China).

Construct of point mutation cell lines

The KYSE140 cell line and KYSE450 cell line were

chosen as the research objects of this study, and CRISPR/Cas9 technology was used to establish the KYSE140 and KYSE450 point mutation cell lines. This experiment was partly completed by Beijing Biocytogen Biotechnology Co., Ltd. (Beijing, China).

Construction of a point mutation cell line was first conducted using the KYSE140 cell line (Figure 1). The point mutation c.1348G>A (pGlu450Lys) was knocked-in to exon 8 of the *NOTCH1* gene. After target sequencing was confirmed, the single-guide RNA (sgRNA) recognition sequence was completely consistent with the DNA sequence of the KYSE140 cell line. According to the design principles of sgRNA, at the 5' target locus, eight sgRNAs were designed for the 3' target site region. After validation, sgRNA5 and sgRNA12 were selected and electrotransformed into the KYSE140 cell line with the targeting vector. After drug screening, positive clone enrichment, and PCR screening, two positive clones were obtained. Then, PCR product sequencing confirmed that the KYSE140 cell line was homozygous for the knock-in point mutation. The KYSE450 point mutation cell line was prepared using the same approach as that used for the KYSE140 cell line, and two positive clones were obtained.

Drug sensitive test

The above groups of cells in the logarithmic growth phase were digested by trypsin (Servicebio G4004, Wuhan, China), seeded in 96-well plates at 5×10^3 cells per well, and incubated for 12 h. Then, cell suspensions were treated with cisplatin (0, 3.1, 6.3, 13, 25, 50 $\mu\text{g}/\text{mL}$) or paclitaxel (0.8, 1.6, 3.1, 6.2, 12.5, 25, 50, 100, 200 $\mu\text{g}/\text{mL}$). After 0, 24, and 48 h of treatment, 10 μL of Cell Counting Kit-8 (CCK-8) reagent (Vazyme, Nanjing, China) was added to each well. After the addition of the CCK-8 reagent, the cells were incubated for another 4 h. Optical density (OD) was measured with a microplate reader (Perlong, Beijing, China). Cell survival rate was calculated as $(\text{OD value of experimental group} - \text{OD value of blank group}) / (\text{OD value of control group} - \text{OD value of blank group}) \times 100\%$. The half-maximal inhibitory concentration (IC_{50}) was calculated using GraphPad Prism 5.0 software to study and evaluate the sensitivity and resistance of cells to cisplatin/paclitaxel.

Wound scratch assay

A marker pen and ruler were irradiated with UV light for 30 min on a clean bench. A horizontal line was drawn on the

back of each six-well plate, and approximately 1×10^5 cells were added to reach confluence overnight. The cell layer was scratched on the second day. After scratching, the cell layer was washed with phosphate-buffered saline (PBS) and incubated in fresh serum-free culture medium in an incubator (37 °C, 5% CO_2). Then, the cells were removed from the incubator at 0 and 24 h and observed under a microscope (quadruple field of view). The scratches were photographed, and the area of the scratch was calculated (UOP DSY5000X, USA). After opening the images in ImageJ, eight horizontal lines were randomly drawn, and the mean value of intercellular distances was calculated.

Transwell cell migration and invasion assay

Cells were digested with trypsin, counted, and adjusted to an appropriate density. In a 24-well Transwell plate (NEST 0223A, China), 400 μL of complete medium was added to the lower chamber, and 200 μL of serum-free cell suspension (NEST 725301, China) was added to the upper chamber. After culturing for 24 h in an incubator, the cells were fixed in paraformaldehyde for 25 min, washed three times with 0.9% NaCl, and stained with crystal violet for 40 min. A multifunctional camera was used to take pictures, and differences between the groups were observed. The measurement values were recorded, and the results were analyzed using GraphPad Prism 5.0 software.

Cell proliferation assay

Cell proliferation was evaluated by the CCK-8 assay. A total of 1×10^3 KYSE140-wild-type (WT)/mutant-type (MT) or KYSE450-WT/MT cells were seeded in each well of a 96-well plate. After overnight incubation, absorbance value was read at a reference of 450 nm. The inhibition rate (%) was calculated as $(1 - \text{OD value of treated group}) / \text{OD value of the control group} \times 100\%$.

Flow cytometry

Propidium iodide staining was used to assess the cell cycle status of the ESCC cell lines in the absence and presence of the *NOTCH1 p.E450K* point mutation. Cells in each group were digested with trypsin, centrifuged and fixed in 75% ethanol, then, propidium iodide staining solution was added and the cells were incubated at room temperature for 30 min in the dark, stored at 4 °C in the dark and analyzed within 24 h. A flow cytometer (BD Biosciences Canto II,




Figure 1 Construction of KYSE140 point MT cell lines. (A) Target sequence sequencing confirmation; (B) Cas9/sgRNA design; (C) Cas9/sgRNA activity detection; (D) after enzyme digestion identification and sequencing, it was confirmed that the construction of the target vector was completed; (E) cell targeting vector map; (F) illustration of the design principles of identification primers; (G) identification of primer information; (H) part of the identification results; (I) positive clones are summarized. Tm, temperature; F, forward; R, reverse; Con, control; PC, positive control; sgRNA, single-guide RNA; HR, homologous recombination; mKI, mutant-type; WT, wild-type.

San Jose, CA, USA) was used to detect red fluorescence at an excitation wavelength of 535 nm and an emission wavelength of 615 nm and light scatter. Cellular DNA content analysis and light scatter analysis were performed using FlowJo analysis software (FlowJo10.2).

The apoptosis rates of the ESCC cell lines in the absence and presence of the *NOTCH1* p.E450K point mutation were determined using an Annexin V-fluorescein isothiocyanate (V-FITC)/propidium iodide (PI) kit (Beyotime C1062S, Shanghai, China). Briefly, the cells were digested, washed, and centrifuged in cold PBS. Staining was performed with Annexin V-FITC and PI at room temperature (15 min). Flow cytometry (BD Biosciences Cantoll) was performed to analyze cell apoptosis. Data were quantified using FlowJo analysis software (FlowJo10.2).

Statistical analysis

The data were statistically analyzed and compared using the statistical software SPSS 23.0 (IBM, Armonk, NY, USA). Each experiment was repeated at least three times, and $P < 0.05$ was considered statistically significant.

Ethical statement

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was reviewed and approved by the Ethics Review Committee of the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital (No. 2021-KY-0049-001).

Results

Sanger sequencing screening

Sequencing results showed that the *NOTCH1* p.E450K point mutation was located in *NOTCH1*-E8 and that KYSE140 and KYSE450 cells did not have exon mutations in the *NOTCH1* ligand binding region in E8. KYSE140 and KYSE450 cells were chosen as the research objects of this study.

Construction of point MT cell lines (CRISPR/Cas9 technology)

The *NOTCH1* gene is approximately 51.4 kb in length and is located on the anti-strand on chromosome 9 (NCBI ID: 4851). After drug screening, the enrichment of positive clones, and PCR screening, two positive clones were finally

obtained. PCR product sequencing showed that 1-A08, 1-B03, 1-A01, and 1-B12 were homozygous knock-in clones of the KYSE140/450 cell lines. The construction and validation of the *NOTCH1* c.1348G>A (pGlu450Lys) point mutation in the two cell lines are shown in *Figure 2*.

NOTCH1 p.E450K point mutation promoted chemotherapy resistance

To study the effect of the *NOTCH1* p.E450K point mutation on chemotherapy resistance in ESCC cell lines, the KYSE140/450 cell lines were treated with cisplatin or paclitaxel.

The inhibition results for the KYSE140-WT/MT and KYSE450-WT/MT cell lines after treatment with different concentrations of cisplatin showed that with increasing concentrations of cisplatin, the inhibitory effect on the KYSE140-WT/MT cell line and the KYSE450-WT/MT cell line gradually increased in a dose-dependent manner, the IC_{50} value of the MT cell line KYSE140-MT/KYSE450-MT was higher than that of the WT cell line KYSE140-WT/KYSE450-WT. Under the same cisplatin concentration, the inhibitory effect of cisplatin on the MT cell line was always weaker than that on the WT cell line (*Figure 3A,3B*), and the difference was significant ($P < 0.001$). This suggests that the *NOTCH1* p.E450K point mutation can reduce the sensitivity of ESCC cell lines to chemotherapeutic agents, which in turn leads to chemoresistance, in terms of IC_{50} , the same conclusion was obtained in the paclitaxel-treated group (*Figure 3C,3D*).

NOTCH1 p.E450K point mutation enhanced the invasion and migration abilities of ESCC cell lines

Through scratch experiments and Transwell experiments, the changes in the migration, invasion and metastasis of the KYSE140/450 cell lines under the effect of the *NOTCH1* p.E450K point mutation were investigated. The results of the scratch experiment showed that the *NOTCH1* p.E450K point mutation resulted in the enhanced invasion and migration abilities of KYSE140 and KYSE450 cells (*Figure 4A,4B*). Transwell experiments showed that the *NOTCH1* p.E450K point mutation enhanced the invasiveness of the KYSE140 and KYSE450 cell lines (*Figure 4C,4D*).

NOTCH1 p.E450K point mutation promoted proliferation

To figure out the effect of *NOTCH1* p.E450K point







Figure 2 CRISPR/Cas9 technology to construct *NOTCH1* p.E450K point MT KYSE140 and KYSE450 esophageal cancer cell lines. (A,C,E,G,I) Illustration of the construction and validation of missense MT cells of the KYSE140 cell line; (B,D,F,H,J) illustration of the construction and validation of missense MT cells of the KYSE450 cell line. (A,B) Schematic diagrams of targeting based on CRISPR/Cas9 technology; (A) knock-in point mutation c.1348G>A (pGlu450Lys) in exon 8 of CL-ZY2-007 gene; (B) knock-in point mutation c.1348G>A (pGlu450Lys) in exon 8 in CL-ZY2-008 gene; (C,D) the cell target vector map; (E,F) the design of positive clone screening primers; (G,H) the PCR positive clone screening results; (I,J) the summary of PCR product sequencing results; (G,I) 1-A08 and 1-B03 are the KYSE140 cell line *NOTCH1* point mutation homozygous knock-in positive clones; (H,J) 1-A01 and 1-B12 are KYSE450 cell line point mutation homozygous knock-in positive clones. HR, homologous recombination; mKI, mut knockin; MT, mutant-type; PCR, polymerase chain reaction.




[Inhibitor] vs. normalized response—variable slope [2]	
Best-fit values	
IC ₅₀	1.260
Hillslope	-2.245
LogIC ₅₀	0.1005
95% CI (profile likelihood)	
IC ₅₀	0.04612 to + infinity
Hillslope	-infinity to -0.5994
LogIC ₅₀	-1.336 to ???
Goodness of fit	
Degrees of freedom	16
R squared	0.9855
Sum of squares	347.7
Sy.x	4.661
Constraints	
IC ₅₀	IC ₅₀ > 0
Number of points	
# of X values	18
# Y values analyzed	18



[Inhibitor] vs. normalized response—variable slope [2]	
Best-fit values	
IC ₅₀	1.074
Hillslope	-2.343
LogIC ₅₀	0.03118
95% CI (profile likelihood)	
IC ₅₀	0.07376 to + infinity
Hillslope	-infinity to -0.7649
LogIC ₅₀	-1.132 to ???
Goodness of fit	
Degrees of freedom	16
R squared	0.9950
Sum of squares	121.4
Sy.x	2.755
Constraints	
IC ₅₀	IC ₅₀ > 0
Number of points	
# of X values	18
# Y values analyzed	18



[Inhibitor] vs. normalized response—variable slope [2]	
Best-fit values	
IC ₅₀	7.451
Hillslope	-0.6584
LogIC ₅₀	0.8722
95% CI (profile likelihood)	
IC ₅₀	4.840 to 11.20
Hillslope	-0.8814 to -0.4844
LogIC ₅₀	-0.6848 to 1.049
Goodness of fit	
Degrees of freedom	8
R squared	0.9581
Sum of squares	366.3
Sy.x	6.767
Constraints	
IC ₅₀	IC ₅₀ > 0
Number of points	
# of X values	10
# Y values analyzed	10



[Inhibitor] vs. normalized response—variable slope [2]	
Best-fit values	
IC ₅₀	9.936
Hillslope	-0.5548
LogIC ₅₀	0.9972
95% CI (profile likelihood)	
IC ₅₀	0.8264 to 96.13
Hillslope	-3.220 to -0.08497
LogIC ₅₀	-0.08283 to 1.983
Goodness of fit	
Degrees of freedom	8
R squared	0.6243
Sum of squares	3539
Sy.x	21.03
Constraints	
IC ₅₀	IC ₅₀ > 0
Number of points	
# of X values	10
# Y values analyzed	10

Figure 3 Results of cell viability detection in each group after different concentrations of chemotherapy drugs. (A,B) Cell viability curve in each group after different concentrations of cisplatin. (C,D) Cell viability curve in each group after different concentrations of paclitaxel. WT, wild-type; MT, mutant-type; IC₅₀, half-maximal inhibitory concentration; CI, confidence interval.




Figure 4 *NOTCH1* *p.E450K* point mutation enhances the migration and invasion ability of KYSE140/KYSE450 esophageal cancer cells, and accelerates the proliferation. (A,B) Wound scratch assay showed that *NOTCH1* *p.E450K* point mutation enhanced the invasion and migration ability of KYSE140/KYSE450 cells. (C,D) Transwell assay (crystal violet staining) showed that *NOTCH1* *p.E450K* point mutation enhanced the invasion and migration ability of KYSE140/KYSE450 cells. (E,F) CCK-8 proliferation assay showed that no significant difference in the proliferation ability of KYSE140/KYSE450 cells before and after *NOTCH1* *p.E450K* point mutation. *, $P < 0.05$; **, $P < 0.01$. WT, wild-type; MT, mutant-type; OD, optical density; CCK-8, Cell Counting Kit-8.

mutation on the proliferation, we compared WT esophageal cancer cell lines with MT esophageal cancer cell lines using CCK-8 assay. There was no statistical significance in the comparison of proliferative ability of ESCC cells before and after *NOTCH1* *p.E450K* point mutation, indicating that point mutation had no significant effect on the proliferation of ESCC cells (Figure 4E, 4F).

The effects of the point mutation on the cell cycle

Flow cytometry analysis showed that the *NOTCH1* *p.E450K* point mutation caused a significant increase in the proportion of KYSE140 and KYSE450 cells in S phase (Figure 5). S phase is the main period of DNA synthesis, also known as the DNA replication phase, during which the DNA number doubles. In general, once cells enter S phase,




Figure 5 Effect of *NOTCH1* p.E450K mutation on cell cycle of esophageal cancer cells. *NOTCH1* p.E450K point mutation caused a significant increase in the proportion of S phase cells in KYSE140/KYSE450 cells. *, $P < 0.05$; **, $P < 0.01$. WT, wild-type; MT, mutant-type.

cell division continues until the G1 phase of the next cycle. An increase in cells in S phase indicates proliferation.

Discussion

Although it has been confirmed in many cancers, including esophageal cancer, that the activation of the *NOTCH1* pathway leads to drug resistance in malignant tumors (7), little is known about the *NOTCH* pathway causing drug resistance in ESCC. In previous reports on ESCC gene sequencing, the frequency of *NOTCH1* mutations was lower only than that of *p53* (11,12). Many studies (13-22) have explained how the activation of the *NOTCH1* signaling pathway leads to chemotherapy resistance. However, these studies mostly addressed the regulation of *NOTCH1* transcription or expression, followed by the abnormal activation of the *NOTCH1* pathway, which leads to chemotherapy resistance. No *NOTCH1* sense mutations have been found, nor reports of *NOTCH1* mutations that affect the ligand binding status of receptors in this pathway, resulting in chemotherapy resistance.

A previous study on drug resistance to nCT in esophageal cancer showed that in patients with ineffective chemotherapy, the detection rate of *NOTCH1* missense mutations was significantly increased (9). Further study found that the p.E450K missense mutation increased the binding ability of the *NOTCH1* receptor protein to its ligand DLL4 (10). On this basis, we investigated the effect of the *NOTCH1* p.E450K missense mutation on cell phenotype to elucidate the biofunctional changes in *NOTCH1* missense mutation cell lines. The results showed that the *NOTCH1* p.E450K point mutation caused chemotherapy resistance in KYSE140 and KYSE450 ESCC cell lines, enhanced cell migration and invasion abilities, and increased the number of cells in S phase.

A study by Xie *et al.* (23) showed that high *NOTCH1* expression promoted resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Zhang *et al.* (24) showed that the *NOTCH* signaling pathway was activated in the erlotinib-resistant NSCLC cell line HCC827/ER. In a

breast cancer study, Pandya *et al.* (25) found that positive human epidermal growth factor receptor 2 (ErbB-2) expression inhibited the transcriptional activity of *NOTCH* and that herceptin treatment activated the *NOTCH* signaling pathway and led to chemotherapy resistance. In the T47D model of tamoxifen-resistant breast cancer, abnormally activated PKC α specifically upregulated the expression of *NOTCH* to cause drug resistance in breast cancer cells (26). Hang *et al.* (27) found that *NOTCH1* was highly expressed in cisplatin-resistant gastric cancer cell lines. Mirone *et al.* (28) found that *NOTCH1* was significantly highly expressed in colorectal cancer (CRC) cell lines that were resistant to regorafenib and that the downregulation of *NOTCH1* expression reversed drug resistance. Huang *et al.* (29) found that in CRC patients, *NOTCH1* was abnormally highly expressed in cells resistant to oxaliplatin and fluorouracil. Takam *et al.* (30) found that *NOTCH1* and the downstream target gene Hes1 of the *NOTCH* signaling pathway were highly expressed in human bone marrow mesenchymal stem cells (hBM-MSCs) from acute myeloid leukemia (AML) patients and that hBM-MSCs mediated and activated the *NOTCH* signaling pathway to promote the proliferation and drug resistance of leukemia cells. In chemotherapy sensitivity studies of breast cancer (31) and prostate cancer (32), it was found that the sensitivity of some patients to chemotherapeutic drugs could be improved by downregulating the *NOTCH1* signaling pathway, suggesting that the *NOTCH1* receptor and its ligand-mediated signaling pathways are closely related to chemotherapy resistance.

In the drug sensitivity test of the KYSE140 ESCC cell lines, the results showed that as the concentration of paclitaxel/cisplatin increased, its inhibitory effect on the KYSE140-WT and KYSE140-MT cell lines gradually increased (cell viability gradually decreased) in a dose-dependent manner. The IC₅₀ results for paclitaxel/cisplatin showed that the IC₅₀ concentration for the cells in the KYSE140-WT group was significantly lower than that for the cells in the KYSE140-MT group ($P < 0.01$), indicating that signaling pathways in the KYSE140 cell line with the *NOTCH* missense mutation may be abnormally activated. Activation leads to the drug-resistant phenotype in tumor cells and the enhancement of chemotherapy resistance in ESCC cell lines. The same conclusion was obtained in the comparison of KYSE450-MT and KYSE450-WT cells.

The *NOTCH* signaling pathway is closely related to cell proliferation and differentiation and plays a very important regulatory role in body development. A number of studies

have found that abnormal *NOTCH* signaling is associated with various common tumors, such as gastric cancer (33), breast cancer (34), lung cancer (35), and liver cancer (36). Some studies (37,38) also found that *NOTCH* signaling is involved in the process of tumor invasion and metastasis. A study on ESCC (7) explored the association between gene mutations in tumor cells and prognosis and chemotherapy response. The results showed that patients with *NOTCH1* mutations survived for a shorter time than patients without *NOTCH1* mutations and patients with *NOTCH1* mutations did not respond to chemotherapy. By comparing pathological staging among patients with HCC, Wang *et al.* (39) found that *NOTCH1* gene expression in patients with late-stage disease (stage III/IV) was higher than that in patients with earlier stage disease (stage I/II), suggesting that the *NOTCH1* gene expression level may be associated with the invasion and metastasis of hepatocellular carcinoma (HCC). Another study (40) found that Jagged1, a *NOTCH* signaling ligand, was associated with the recurrence and metastasis of prostate cancer. Some studies (41,42) have confirmed that the *NOTCH* pathway can synergize with other tumor signaling pathways, such as the *EGFR*, *Ras*, and *Akt* signaling pathways, which are very important for tumor development.

In this study, in the scratch and Transwell experiments, the MT cell line had stronger invasion and migration abilities than the WT cell line ($P < 0.05$). Flow cytometry analysis also showed that the proportion of cells in S phase among the MT cells was significantly higher than that among WT cells, and proliferation test results showed that the proliferation ability of *NOTCH1* mutation cell line was enhanced. In general, once cells enter S phase, cell division continues until the G1 phase of the next cycle. An increase in the number of tumor cells in S phase indicates tumor cell proliferation and increases the ability of tumor cells to resist chemotherapy.

In the KYSE140 and KYSE450 ESCC cell lines, the *NOTCH1 p.E450K* point mutation enhanced the migration and invasion abilities and increased the percentage of cells in S phase. Although cell function experiments have yielded satisfactory results, they only reflect laboratory conditions, and therefore, further verification is needed by carrying out corresponding animal tumor model experiments. ESCC is a malignant tumor with high incidence and strong invasiveness. Although nCT has achieved good effects, resistance of tumor cells to chemotherapy is still a problem. If the mechanism underlying the involvement of the *NOTCH* signaling pathway in cell drug resistance is elucidated, it may provide new therapeutic targets and

targeted pathways for molecular targeted therapy for the reversal of drug resistance in esophageal cancer. This missense mutation may be a potential predictor of clinical chemotherapy efficacy and an important target for the reversal of drug resistance, which is worthy of further study.

Conclusions

The *NOTCH1 p.E450K* point mutation causes chemotherapy resistance in KYSE140 and KYSE450 ESCC cells. Cell functional experiments showed that the *NOTCH1 p.E450K* point mutation enhanced the proliferation, migration and invasion abilities of KYSE140 and KYSE450 cells and increased the number of cells in S phase; the mutation had no effect on apoptosis.

Acknowledgments

Funding: This work was supported by the National Natural Science Foundation of China, NSFC (grant No. 82002521), the Natural Science Foundation of Henan Province, China (grant No. 202300410389), the Henan Anti-Cancer Association Youth Talent Project, China (grant No. 2019HYTP018, 2019), the Wu Jieping Medical Foundation (CN), China (grant No. 320.6750.2020-15-1), the Henan Province Health Science and Technology Innovation Outstanding Young Talents Training Project, China (YXKC2021029), and the Henan Province Medical Science and Technology Key Projects Co-Constructed by the Ministry of Health, China (Thoracic Surgery-3202730).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1880/rc>

Data Sharing Statement: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1880/dss>

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1880/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1880/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was reviewed and approved by the Ethics Review Committee of the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital (No. 2021-KY-0049-001).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
2. Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. *Gut* 2015;64:381-7.
3. Zheng Y, Li Y, Liu X, et al. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. *Medicine (Baltimore)* 2015;94:e1102.
4. Wang E, Zaman N, Mcgee S, et al. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. *Semin Cancer Biol* 2015;30:4-12.
5. Dang TP. Notch, apoptosis and cancer. *Adv Exp Med Biol* 2012;727:199-209.
6. Hu YY, Zheng MH, Zhang R, et al. Notch signaling pathway and cancer metastasis. *Adv Exp Med Biol* 2012;727:186-98.
7. Song B, Cui H, Li Y, et al. Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. *Oncotarget* 2016;7:3599-613.
8. Zhang H, Jiang H, Chen L, et al. Inhibition of Notch1/Hes1 signaling pathway improves radiosensitivity of

- colorectal cancer cells. *Eur J Pharmacol* 2018;818:364-70.
9. Liu J, Xing W, Tian Q, et al. Application of next-generation sequencing in resistance genes of neoadjuvant chemotherapy for esophageal cancer. *Transl Cancer Res* 2020;9:4847-56.
 10. Gao K, Xing W, Liu X, et al. The Notch1 gene may control cell chemoresistance in esophageal squamous cell cancer. *Transl Cancer Res* 2021;10:3278-85.
 11. Gao YB, Chen ZL, Li JG, et al. Genetic landscape of esophageal squamous cell carcinoma. *Nat Genet* 2014;46:1097-102.
 12. Zhang L, Zhou Y, Cheng C, et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. *Am J Hum Genet* 2015;96:597-611.
 13. Alcolea MP, Jones PH. Cell competition: winning out by losing notch. *Cell Cycle* 2015;14:9-17.
 14. Kang M, Jiang B, Xu B, et al. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. *Cancer Lett* 2013;330:11-21.
 15. Cenciarelli C, Marei HE, Zonfrillo M, et al. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets. *Oncotarget* 2017;8:17873-86.
 16. Lee CW, Raskett CM, Prudovsky I, et al. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. *Cancer Res* 2008;68:5273-81.
 17. Roodhart JM, He H, Daenen LG, et al. Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance. *Blood* 2013;122:143-53.
 18. Zhang Y, Xu W, Guo H, et al. NOTCH1 Signaling Regulates Self-Renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-Small Cell Lung Cancer. *Cancer Res* 2017;77:3082-91.
 19. Chen Y, Li D, Liu H, et al. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. *Cancer Biol Ther* 2011;11:14-21.
 20. Katoh M, Katoh M. Notch signaling in gastrointestinal tract (review). *Int J Oncol* 2007;30:247-51.
 21. Joshi I, Minter LM, Telfer J, et al. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. *Blood* 2009;113:1689-98.
 22. Sun B, Dong C, Lei H, et al. Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway. *Chem Biol Interact* 2018;294:28-33.
 23. Xie M, He CS, Wei SH, et al. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. *Eur J Cancer* 2013;49:3559-72.
 24. Zhang H, Chen F, He Y, et al. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway. *Biosci Rep* 2017;37:BSR20160478.
 25. Pandya K, Wyatt D, Gallagher B, et al. PKC α Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. *Clin Cancer Res* 2016;22:175-86.
 26. Yun J, Pannuti A, Espinoza I, et al. Crosstalk between PKC α and Notch-4 in endocrine-resistant breast cancer cells. *Oncogenesis* 2013;2:e60.
 27. Hang Q, Sun R, Jiang C, et al. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. *Anticancer Drugs* 2015;26:632-40.
 28. Mirone G, Perna S, Shukla A, et al. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. *J Cell Physiol* 2016;231:1097-105.
 29. Huang R, Wang G, Song Y, et al. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. *Mol Med Rep* 2015;12:2417-24.
 30. Takam Kamga P, Bassi G, Cassaro A, et al. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. *Oncotarget* 2016;7:21713-27.
 31. Kang L, Mao J, Tao Y, et al. MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. *Cancer Sci* 2015;106:700-8.
 32. Liu X, Luo X, Wu Y, et al. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. *Cell Physiol Biochem* 2018;50:261-76.
 33. Li GG, Li L, Li C, et al. Influence of up-regulation of Notch ligand DLL4 on biological behaviors of human gastric cancer cells. *World J Gastroenterol* 2013;19:4486-94.
 34. Mittal S, Subramanyam D, Dey D, et al. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. *Mol Cancer* 2009;8:128.
 35. Xu K, Moghal N, Egan SE. Notch signaling in lung development and disease. *Adv Exp Med Biol* 2012;727:89-98.
 36. Villanueva A, Alsinet C, Yanger K, et al. Notch signaling

- is activated in human hepatocellular carcinoma and induces tumor formation in mice. *Gastroenterology* 2012;143:1660-1669.e7.
37. Bolós V, Mira E, Martínez-Poveda B, et al. Notch activation stimulates migration of breast cancer cells and promotes tumor growth. *Breast Cancer Res* 2013;15:R54.
 38. Chen J, Imanaka N, Chen J, et al. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. *Br J Cancer* 2010;102:351-60.
 39. Wang XQ, Zhang W, Lui EL, et al. Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. *Int J Cancer* 2012;131:E163-72.
 40. Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. *Cancer Res* 2004;64:6854-7.
 41. Osipo C, Golde TE, Osborne BA, et al. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. *Lab Invest* 2008;88:11-7.
 42. Sundaram MV. The love-hate relationship between Ras and Notch. *Genes Dev* 2005;19:1825-39.

Cite this article as: Li K, Hao W, Wu J, Liu X, Xing W, Zheng Y. Biofunctional study on chemoresistance in esophageal squamous carcinoma cells induced by missense mutation of *NOTCH1* p.E450K. *J Thorac Dis* 2024;16(3):1947-1959. doi: 10.21037/jtd-23-1880